Addressing Ruxolitinib Resistance in Myelofibrosis
Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis after failure on ruxolitinib (Jakafi).<br />
Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, addresses the management of patients with myelofibrosis (MF) after failure on ruxolitinib (Jakafi).
Ruxolitinib failure is observed in a broad range of presentations and definitions, and Scherber says that a key difference should specifically be made between ruxolitinib refractory/resistant patients and ruxolitinib progressed/relapsed patients. Scherber says that she evaluates which category a patient falls into once they have failed on ruxolitinib, and then adjusts treatment accordingly.
Ropeginterferon Alfa-2b Succeeds in Phase 3 Essential Thrombocythemia Trial
January 6th 2025The SURPASS-ET trial demonstrated ropeginterferon alfa-2b's superior efficacy over anagrelide, achieving higher durable response rates and greater reduction in JAK2 allele burden among patients with essential thrombocythemia.
Read More
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
December 29th 2024In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant impact on patients with rare diseases receiving medical care and why the rules from the COVID-19 era should be brought back to continue helping these patients.
Read More
Brunner Discusses Dosing Approaches for ESA and Novel Therapies for Low-Risk MDS
December 23rd 2024During a Case-Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as dose modifications and safety for the novel agents imetelstat and luspatercept.
Read More
